HCPCS Level II code C9358 identifies a native, non-denatured fetal bovine collagen dermal substitute (Surgimend collagen matrix) billed per 0.5 square centimeters. The code captures use of a biologic dermal graft in soft-tissue reconstruction and wound repair, which is clinically significant as biologic matrices are increasingly used to support healing in complex surgical and reconstructive procedures. Nationally, use of dermal substitutes affects outpatient surgical resource utilization and specialty supply management.

Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9358 represents, the typical clinical settings for its application, and the payer landscape addressed. The publication provides benchmarks where available, summaries of relevant coverage patterns and coding considerations, and clinical context regarding the service line. Data not available in the input will be noted as such. This summary is intended to help billing professionals, clinical administrators, and policy analysts understand the coding designation and its role in surgical supply reporting and reimbursement workflows.